PDE1A and pulmonary arterial hypertension: In conclusion, this GWAS in I/HPAH patients, irrespective of the presence of a BMPR2 mutation, provided additional information about the association between a genetic locus, PDE1A|DNAJC10, and the disease, suggesting that PDE1A could be a novel therapeutic target of PAH.